title: [Alfadil and heart failure--clinical conclusions do exist!].
authors.affiliation: Pfizer AB, Täby. leif.lohm@pfizer.com
authors.forename: Leif
authors.initials: L
authors.lastname: Lohm
authors.forename: Erik
authors.initials: E
authors.lastname: Lindh
authors.forename: Roland
authors.initials: R
authors.lastname: Frösing
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D004346:Drug Information Services; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D017410:Practice Guidelines as Topic; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D017292:Doxazosin